Liver Glucokinase\textsubscript{A456V} Induces Potent Hypoglycemia without Dyslipidemia through a Paradoxical Induction of the Catalytic Subunit of Glucose-6-Phosphatase

Anna Vidal-Alabró, Alicia G. Gómez-Valadés, Andrés Méndez-Lucas, Jordi Llorens, Ramon Bartrons, Jordi Bermúdez, and Jose C. Perales

Biophysics Unit, Department of Physiological Sciences II, IDIBELL-University of Barcelona, Campus de Bellvitge, 08907 L'Hospitalet de Llobregat, Spain

Correspondence should be addressed to Jose C. Perales, jperales@ub.edu

Received 4 August 2011; Accepted 9 September 2011

Academic Editor: Maria L. Dufau

Copyright © 2011 Anna Vidal-Alabró et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Recent reports point out the importance of the complex GK-GKRP in controlling glucose and lipid homeostasis. Several GK mutations affect GKRP binding, resulting in permanent activation of the enzyme. We hypothesize that hepatic overexpression of a mutated form of GK, GK\textsubscript{A456V}, described in a patient with persistent hyperinsulinemic hypoglycemia of infancy (PHHI) and could provide a model to study the consequences of GK-GKRP deregulation in vivo. GK\textsubscript{A456V} was overexpressed in the liver of streptozotocin diabetic mice. Metabolite profiling in serum and liver extracts, together with changes in key components of glucose and lipid homeostasis, were analyzed and compared to GK wild-type transfected livers. Cell compartmentalization of the mutant but not the wild-type GK was clearly affected in vivo, demonstrating impaired GKRP regulation. GK\textsubscript{A456V} overexpression markedly reduced blood glucose in the absence of dyslipidemia, in contrast to wild-type GK-overexpressing mice. Evidence in glucose utilization did not correlate with increased glycogen nor lactate levels in the liver. PEPCK mRNA was not affected, whereas the mRNA for the catalytic subunit of glucose-6-phosphatase was upregulated ∼4 folds in the liver of GK\textsubscript{A456V}-treated animals, suggesting that glucose cycling was stimulated. Our results provide new insights into the complex GK regulatory network and validate liver-specific GK activation as a strategy for diabetes therapy.

1. Introduction

Glucokinase (GK) (EC 2.7.1.1) is expressed in glucosensitive cells of the pancreas, liver, hypothalamus, anterior pituitary gland, and enteroendocrine K and L cells [1–3]. GK has a prominent role as a glucose sensor because of its specific kinetic properties, including an affinity for glucose that is within the physiological plasma concentration range (half-saturation level for glucose \(S_{0.5}\) of ∼8 mmol/L), positive cooperativity, and lack of inhibition by glucose-6-phosphate. In liver and brain, GK is controlled by an endogenous inhibitor, the glucokinase regulatory protein (GKRP) [4, 5]. During starvation, the enzyme is bound to GKRP, leading to its inactivation and sequestration in the nucleus. After refeeding, glucose mediates the dissociation of the GK-GKRP complex and GK translocates to the cytoplasm. Also, several naturally occurring activating mutations have been described that induce a conformational change in GK, which results in higher affinity for glucose, and reduce the interaction between GK and GKRP [6, 7]. One such mutation, A456V, completely impairs GK-GKRP complex. Similarly, synthetic GK activators (GKAs) enhance GK activity and induce its translocation to the cytosol [8–12].

There is evidence that a defect in GKRP regulation of GK, resulting in increased liver GK activity probably as a result of increased cytosolic translocation, has consequences on glucose and triglyceride homeostasis in humans, even though these patients have reduced risk to type 2 diabetes [13, 14].

We aimed to study the metabolic consequences of GK-GKRP deregulation by overexpressing a GK activating
mutant (GK_A456V) in the liver of insulin-deficient mice (lacking endogenous GK). Transfected GK_A456V is maintained in the cytosol of hepatocytes in vivo leading to improved glycemia in the absence of dyslipidemia. These data provide novel insights into the consequences of GK-GKRP derangement and widen the scope for GKA research in the liver.

2. Materials and Methods

2.1. Directed Mutagenesis. The cDNA Encoding Rat GK was Kindly Provided by Dr. Fatima Bosch (CBATEG, Universitat Autònoma de Barcelona). Site-Directed Mutagenesis to Generate GK-A456V cDNA Was Performed Using the QuickChange Site-Directed Mutagenesis Kit (Stratagene), and Specific Primers Containing the Desired Mutation (3′-TGGTCTCTGGCGGCGCTGCAAGAAG5′ and 5′-GACCA-GAGACGCCGCGGTGCAGAACG3′) from Dharmacon. Successful Incorporation of the Mutation Was Confirmed by DNA Sequence Analyses.

2.2. Plasmid Construction and Kinetic Analysis of Expressed GKS. The cDNAs for GK and GK_A456V were cloned into EcoRI-BglII of a pcAGs vector which contains the CAG (cytomegalovirus immediate-early enhancer-chicken β-actin hybrid) promoter [15]. The resulting plasmids pGK and pGKA456V were amplified in E. coli JM109 cells and extracted using NucleoBond PC 2000 EF Mega Prep kit (Macherey-Nagel). DNA for animal injection was digested with SalI and HindIII which cut on both sides of the expression cassette [16, 17] in order to extend expression in vivo. Later, DNA was purified by phenol/chloroform extraction. Expression plasmids were transfected in HuH7 cells for kinetic analysis (Supplementary Figure 1 available at doi: 10.1155/2011/707928).

2.3. Animal Care and Treatment. Male ICR mice purchased from Harlan Interfarma IBERICA S.I. were maintained in a constant 12-hour light-dark cycle and fed standard rodent chow and water ad libitum. All animal protocols were approved by the Ethics Committee at the University of Barcelona. To obtain diabetic animals, mice weighing approximately 22 g were injected i.p. with a single dose of streptozotocin (STZ) (200 mg/kg) dissolved in 100 mM citric/citrate buffer, pH 4.5. One week later, glycermia was assessed after a 5-hour fast. Only those mice that had glycermia over 350 mg/dL were used. Digested plasmid DNA was introduced into murine livers using a hydrodynamic-based gene transfer technique via rapid injection of a large volume of DNA solution through the tail vein [18]. Briefly, 60 μg/mouse DNA was diluted in 2.0 to 2.5 mL of apyrogenic Ringer-lactate solution (Fresenius Kabi) (0.1 mL/g body weight) and injected into the tail vein using a 27-gauge needle and syringe within 5 to 10 seconds. Typically, the mice recovered from the injection within 2 to 10 min. At the end of the experiment, animals were sacrificed under xylazine/ketamine anesthesia. Blood samples were taken by inferior cava vein puncture and serum was obtained by centrifugation at 700×g at 4°C for 15 min. Liver was dissected, snap frozen in liquid nitrogen, and subsequently stored at −80°C until analysis.

2.4. Immunohistochemistry. For GK immunodetection, livers from 5-hour fasted animals were fixed in a 4% PFA solution and frozen in OCT compound. 7 μm cryosections were obtained in a cryostat and immunostained with a 1:50 dilution of GK antibody (AP7901c, Abgen) followed by an anti-rabbit antibody Alexa Fluor 488 (Molecular Probes).

2.5. Blood Metabolite Assays. Blood glucose levels were measured using a Glucocard Memory 2 apparatus (Menarini) from a blood drop collected from the tail tip. The Veterinary Clinical Biochemistry Service from the Veterinary Hospital of the Universitat Autònoma de Barcelona, Bellaterra, Spain, measured serum metabolites. Serum insulin was determined using Ultrasensitive Mouse Insulin ELISA (Mercodia AB).

2.6. RNA Extraction and Quantitative. RT-PCR Total RNA was extracted with RNAeasy mini kit (Quiagen). cDNA synthesis was performed using Ready-To-Go You-Prime First Strand Beads (Amersham Biosciences) with random hexamers. mRNA levels of the transgenic rat GK (r-GK) were quantified with specie-specific primers (Applied Biosystems) and normalized using β-2-microglobulin as an internal control in an HT7700 Real Time-PCR system (Applied Biosystems). Data analysis was based on the ΔΔCt method (Applied Biosystems).

mRNA levels of selected genes of interest were measured running a Low Density Array (Applied Biosystems) in an HT7990 Real Time-PCR system (Applied Biosystems). Expression was normalized using β-2-microglobulin as an endogenous control. Data analysis followed the ΔΔCt method.

2.7. GK Activity. Frozen liver samples were homogenized in ice-cold homogenization buffer (HEPES 50 mM pH 7.4, KCl 100 mM, EDTA 1 mM, MgCl2 5 mM, DTT 2.5 mM) using a polytron PT 3000 and centrifuged at 100,000×g for 1 hour at 4°C. Supernatants were used for the determination of GK activity following the spectrophotometric method described by Davidson and Arion [19]. Briefly, the assays were carried out in a solution containing HEPES 50 mM pH 7.4, KCl 100 mM, MgCl2 7.5 mM, NAD+ 1 mM, ATP 5 mM, BSA 1% and indicated amounts of glucose. The reactions were initiated by adding 5 μL/mL of glucose-6-phosphate dehydrogenase (G6PDH) from Leuconostoc mesenteroides (Roche) and the rate of increase in absorbance at 340 nm was measured. The GK activity was calculated as the difference between the kinase activities measured at different glucose concentrations and 0.5 mM glucose (hexokinase activity), and was expressed as mUnits/mg liver.

2.8. G6PDH Activity. Frozen liver samples were homogenized in ice-cold buffer, which contained HEPES 50 mM pH 7.4, KCl 100 mM, EDTA 1 mM, MgCl2 5 mM, DTT 2.5 mM, and 1% pluronic F-127 (Calbiochem), and centrifuged at 20,000×g for 20 min at 4°C. G6PDH activity was assayed
by measuring the rate of NADPH production from NADP\(^+\) 0.5 mM and glucose-6-phosphate 2 mM, at pH 7.6 [20]. Results were expressed as mUnits/mg protein in the supernatant. Protein was measured using the Bradford method (Bio-Rad).

2.9. Western Blot. Frozen tissue was homogenized in radioimmunoprecipitation assay buffer (RIPA) supplemented with protease and phosphatase inhibitors and centrifuged at 15,000 \(\times\) g for 15 min at 4°C. 30 \(\mu\)g of tissue extract was resolved by SDS-PAGE (8–12% gel) and electrotransferred onto a Hybond-P membrane (Amersham Biosciences). Antibody against GK (H-88, Sta Cruz) was used at 1/500 dilution. 1/1000 dilution was used for the following antibodies: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase (ub-PFK2) and L-pyruvate kinase (L-PK) (gifts from Ramon Bartrons, Barcelona University), and Carbohydrate Response Element Binding Protein (CHREBP) (Novus Biologicals). ACC and ACC-P Ser-79 (Upstate) were used at 1/2000. Sheep anti-PEPCK-C antiserum (a gift from Daryl Granner, Vandervilt University, USA) was used at 1 : 20,000 dilution. All membranes were normalized using monoclonal anti-\(\gamma\)-tubulin (Sigma) at 1 : 10,000 dilution. Horseradish peroxidase activity linked to secondary antibody was detected with ECL substrate (Pierce) in a Fujifilm LAS 300 Intelligent Dark Box IV imaging system. Densitometry was performed using Multi Gauge Software.

2.10. Hepatic Metabolites. To measure hepatic free glucose, glucose-6-phosphate (G6P), and lactate, acid homogenates were obtained from frozen liver. Briefly, perchloric acid 10% was added to frozen pieces of liver (5 : 1 \(v:\text{w}\)) and the mixture was homogenized in a Potter Elvehjem apparatus at 1,500 rpm. The homogenate was then centrifuged at 20,000 \(\times\) g for 10 min at 4°C. The supernatant was brought to pH 7 with K\(_2\)CO\(_3\) 4 N and centrifuged again to remove the KClO\(_4\) formed during neutralization. Free glucose was measured using a Glucose Oxidase kit (Sigma). G6P was measured following the spectrofluorometric method described by Lang & Michal, which is based in the reaction catalyzed by G6PDH. Briefly, the assay solution contained triethanolamine 0.2 M pH 7.6, NADP\(^+\) 0.2 M, MgCl\(_2\) 5 mM, and G6PDH 0.17 U/mL. Lactate was determined by a spectrophotometric method based on the reaction catalyzed by lactate dehydrogenase, following Gutmann & Wahlefeld. Briefly, the reaction cuvette contained hydrazine/glycine buffer 0.25 M/0.7 M, pH 9.3, EDTA 0.15 mM, NAD\(^+\) 2 mM, and 35 U/mL of lactate dehydrogenase.

For fructose-2,6-bisphosphatase (F2,6bP) determination, frozen livers were homogenized in 0.1 M NaOH, heated to 80°C for 15 min, and centrifuged at 12,000 \(\times\) g for 5 min. F2,6bP was determined in supernatants by its ability to activate pyrophosphate-dependent 6-phosphofructo-1-kinase from potato tubers, as described by Van Schaftingen et al. [21].

The hepatic triacylglyceride (TAG) content was measured in 3 M KOH, 65% ethanol extracts using a TAG kit (Sigma), based on the method of Salmon and Flatt for liver saponification.

Hepatic glycogen content was measured essentially as described elsewhere [22].

2.11. Whole-Body Glucose Utilization. A solution of U\(^{14}\)C-glucose and glucose was intraperitoneally injected into 5-hour fasted STZ-diabetic mice (0.2 mg glucose, 10 \(\mu\)Ci per animal). Blood, liver, brain, and muscle were obtained 30 minutes after injection and dissolved into Solvable (Perkin-Elmer). The solution was then loaded onto a thin-layer chromatography plate (Whatman, UK) for analysis.

**Figure 1**: Rat GK and GK\(_{A456V}\) overexpression in the livers of STZ-treated mice. 60 \(\mu\)g of pControl, pGK, or pGK\(_{A456V}\) were hydrodynamically-transfected to diabetic mice. (a) GK protein content of liver homogenates was determined by Western blot. A representative blot and densitometric analysis is shown. (b) Further confirmation of GK overexpression was obtained by analysis of specific GK activity in liver extracts at different glucose concentration. Values are expressed as the means ± SE (\(N = 4, *P < 0.05\) versus pControl).
Blood samples were bleached with EDTA 0.1 M and H$_2$O$_2$ (30%), and liver and brain samples were bleached with H$_2$O$_2$ (30%) alone. Radioactivity was quantified by adding scintillation liquid (Ecoscint H) and counted in a Wallac 1409-001 counter.

2.12. Statistical Analysis. Results are expressed as the mean ± standard error (SE). Statistical analysis was performed by one-way ANOVA with Bonferroni posttest. Differences were considered significant when $P < 0.05$.

3. Results

3.1. Liver Overexpression of pGK and pGKA$^{A456V}$. pGKA$^{A456V}$, wild-type GK (pGK) and an empty vector (pControl), were introduced into the liver of streptozotocin (STZ-) treated mice. Hydrodynamic-based delivery of plasmid DNA led to specific transfection of hepatocytes around the central vein [23, 24], reproducing the physiologic distribution of GK in the liver acinus [25]. This technique induces a transient release of liver enzymes that returns to control values by the second day after injection. Consistently, transaminase levels were low at the end-point of analysis, and similar in all treatment groups (pControl 207.5 ± 29.88 U/L, pGK 121.0 ± 48.43 U/L, pGKA$^{A456V}$ 117.5 ± 40.35 U/L; $n = 4–9$).

At the time of injection mice were hyperglycemic (>350 mg/dL) and their insulin level was undetectable (<0.1 μg/L). Forty-eight hours postinjection the expression of transfected rat GK and GKA$^{A456V}$ was detected by RT-PCR (data not shown). Further confirmation of GK overexpression was obtained by Western blot from liver extracts (Figure 1(a)) and GK activity assay (Figure 1(b)). GK activity was undetectable in pControl transfected livers irrespective of glucose concentration, as expected in long-term STZ diabetic animals. In contrast, both pGK and pGKA$^{A456V}$ transfected groups had similar GK activity at 100 mM glucose (mU/g fresh), demonstrating that both treatment groups had similar amounts of GK protein. Consistent with the $S_{0.5}$ for glucose of GKA$^{A456V}$, liver extracts from pGKA$^{A456V}$-injected animals had twice the GK activity of

**Figure 2:** GK and GKA$^{A456V}$ localization inside hepatocytes. Liver sections of 5-hour fasted mice injected with pControl, pGK, or pGKA$^{A456V}$ were immunostained with GK antibody. TO-PRO-3 was used to visualize nuclei.
3.2. Different Compartmentalization of GK and \( \text{GK}_{\text{A456V}} \). GKRP retains GK in the nucleus at low glucose concentrations and releases GK when insulin, high glucose, or fructose-1P are present [26, 27]. Different studies have suggested that the A456V mutation impairs GKRP regulation in vitro [6, 28]. Therefore, we assessed GKRP-dependent nuclear sequestration in primary hepatocytes from STZ-treated rats transfected with pGK and \( \text{GK}_{\text{A456V}} \), in the presence or absence of pGKR. Densitometry analysis of Western blots from nuclear and cytosolic fractions showed that cellular \( \text{GK}_{\text{A456V}} \) distribution was not affected by the presence of GKRP (data not shown). We next examined the compartmentalization of GK and \( \text{GK}_{\text{A456V}} \) in vivo by immunohistochemistry. pGK-treated mice showed GK immunoreactivity throughout the liver, especially in nuclei (Figure 2). Interestingly, overexpressed \( \text{GK}_{\text{A456V}} \) protein was localized predominantly in the cytosol of transfected hepatocytes. These data demonstrates, that impaired GKRP binding to \( \text{GK}_{\text{A456V}} \) changes its compartmentalization in vivo.

3.3. Glucose Homeostasis in Fed Animals. The impact of both GK enzymes on glucose metabolism was first evaluated in fed animals. Both GK and \( \text{GK}_{\text{A456V}} \) slightly reduced glycemia (Figure 3(a)). To explore the fate of glucose in the liver, we measured several metabolites in hepatic extracts (Table 1). Fed pGK-treated mice showed significantly higher F2,6BP and glycogen contents (Figure 4(a)), together with a rise in lactate, indicating a higher glycolytic flux. \( \text{GK}_{\text{A456V}} \)-expressing livers also showed higher hepatic free glucose than both control and GK groups, even though the content of G6P was similar in all three groups. Furthermore, both F2,6BP and lactate content were increased. Glycogen content was significantly higher than control but similar to pGK-treated group (Figure 4(a)).

3.4. Glucose Homeostasis in 5-Hour Fasted Animals. pGK\(_{\text{A456V}}\)-treated animals showed a marked reduction of glycemia after a 5-hour fast (Figure 3(a)). Lactate was only increased after pGK treatment (pControl, \( 7.296 \pm 0.772 \) mM; pGK\(_{\text{A456V}}\), \( 8.778 \pm 0.649 \) mM; pGK, \( 10.62 \pm 0.608 \) mM— \( P < 0.05 \) versus pControl and pGK\(_{\text{A456V}}\)—). Hepatic free glucose content was low in the pGK\(_{\text{A456V}}\) treatment group (Table 1). G6P levels were reduced to the same extent in control and GK\(_{\text{A456V}}\) groups, whereas GK-expressing animals showed similar G6P and ATP concentrations to well-fed animals. F2,6BP and lactate levels remained higher in both treatment groups as compared to control. Glycogen content in GK-expressing animals was significantly higher than control and GK\(_{\text{A456V}}\)-expressing groups. Fed-to-fast transition produced a marked reduction of glycogen stores in pGK\(_{\text{A456V}}\)-treated animals as compared to pControl and pGK, suggesting an increased rate of glycogenolysis in GK\(_{\text{A456V}}\)-expressing animals (Figure 4(b)). In order to clarify whether glucose distribution in vivo favored the liver, we quantitated \(^{14}\text{C}\) radioactivity derived from uptake and metabolism of \(^{14}\text{C}\)-glucose in various tissues 30 minutes after injection. \(^{14}\text{C}\) label was increased exclusively in the liver of both pGK and pGK\(_{\text{A456V}}\) treatment groups (control, \( 100 \pm 7.88\% \); GK, \( 138.73 \pm 14.63\% \); GKA456V, \( 144.1 \pm 8.99\% \); \( P = 0.037 \) GK versus control and \( P = 0.003 \) pGK\(_{\text{A456V}}\) versus control). To assess whether pGK\(_{\text{A456V}}\) expression would affect glucose clearance in healthy mice, we performed a glucose tolerance test 1 week after transfection (Figure 3(b)).

Liver GK overexpression has been associated with dislipidemia [29]. Consistently, our data demonstrates a significant increase in serum TAG (pControl \( 33.5 \pm 7.72 \) mg/dL, pGK\(_{\text{A456V}}\) \( 38.13 \pm 7.66 \) mg/dL, pGK \( 74.00 \pm 14.76 \) mg/dL,
Table 1: Liver metabolites of STZ-diabetic mice transfected with pControl, pGK and pGK_A456V.

|                     | Fed                  | 5 h-Fasted             |
|---------------------|----------------------|------------------------|
|                     | pControl             | pGK                    | pGK_A456V              | pControl             | pGK                    | pGK_A456V              |
| Glc (μmol/g liver)  | 40.70 ± 5.921        | 32.72 ± 1.475          | 47.68 ± 7.328          | 52.29 ± 9.524        | 32.23 ± 12.18          | 6.35 ± 4.043*          |
| n                   | 11                   | 6                      | 9                      | 5                    | 4                      | 4                      |
| G6P (μmol/g liver)  | 0.16 ± 0.021         | 0.14 ± 0.018           | 0.15 ± 0.021           | 0.06 ± 0.024         | 0.20 ± 0.068§          | 0.04 ± 0.017           |
| n                   | 11                   | 8                      | 10                     | 5                    | 4                      | 5                      |
| F2,6BP (nmol/g liver) | 1.19 ± 0.215        | 2.84 ± 0.625*          | 1.90 ± 0.517           | 0.71 ± 0.173         | 9.86 ± 1.812§          | 4.14 ± 1.607           |
| n                   | 12                   | 8                      | 10                     | 5                    | 5                      | 5                      |
| Lactate (μmol/g liver) | 1.31 ± 0.275       | 1.78 ± 0.424           | 2.27 ± 0.951           | 1.16 ± 0.239         | 1.28 ± 0.322           | 1.32 ± 0.222           |
| n                   | 12                   | 8                      | 10                     | 5                    | 5                      | 5                      |
| TAG (mg/g liver)    | 6.25 ± 0.26          | 6.08 ± 0.36            | 6.26 ± 0.17            | 9.18 ± 1.48          | 12.56 ± 0.50           | 11.84 ± 2.13           |
| n                   | 12                   | 8                      | 10                     | 5                    | 5                      | 5                      |
| GSH/GSSG ratio      | 11.73 ± 0.87         | 11.81 ± 0.93           | 11.37 ± 0.87           | 5.372 ± 0.49         | 9.479 ± 1.38           | 9.926 ± 1.84*          |
| n                   | 12                   | 8                      | 10                     | 5                    | 5                      | 5                      |

Data are means ± SE. (N = 4–12). *P < 0.05 versus pControl; §P < 0.05 versus fast pControl and fast pGK_A456V.

Figure 4: Effects of GK and GK_A456V overexpression on glycogen and glucose-6-phosphate DH activity in the liver. (a) Glycogen levels from fed and 5-hour fasted mice. (b) Glycogen balance between the fast and fed transition. (c) Glc6P DH activity was measured in liver extracts of mice in fed and fasted state. (d) Variation of Glc6P DH activity during the fed-to-fast transition. Data are mean ± SE. (N = 5–9. *P < 0.05 versus pControl; §P < 0.05 versus pControl and P < 0.01 versus pGK; ΔP < 0.05 versus pControl and pGK).
enzymes and transcription factors involved in de novo lipogenesis were analyzed. GK- and pGKA456V-expressing groups presented increased mRNA content for Fasn and Mod1 that were more pronounced in pGK-treated animals. Also, Acc1 and Chrebp were more induced by the overexpression of GK than by GKA456V.

GK, through the production of xylulose-5P, mediates the inhibition of gluconeogenesis by glucose [34, 35]. F2,6BP [36] has also been associated with the inhibitory effect of glucose metabolism on gluconeogenesis. Consistently, we observed a reduction of PEPCK at the protein level in both pGK- and pGKA456V-treated mice. However, PEPCK mRNA was reduced only in GK-overexpressing animals. Similarly, PGC-1α and HNF4α mRNAs were reduced in pGK-injected mice, whereas GKA456V-overexpressing livers only showed reduced PGC-1α mRNA.

In contrast, the level of mRNA for the catalytic subunit of glucose-6-phosphatase (Glc6Pase) were strikingly higher than by GKA456V. Also, Acc1 and Chrebp were more induced by the overexpression of GK than by GKA456V.

4. Discussion

To evaluate the consequences of GK activation and deregulation by GKR in the liver, we hydrodynamically injected pGKA456V in the liver of STZ-diabetic mice. This strategy

| Gene          | Protein    | pControl | pGK      | pGKA456V |
|---------------|------------|----------|----------|----------|
| Glycolysis and lipogenesis | | | | |
| Gck           | GK         | 1.26 ± 0.72 | 5.28 ± 1.49 | 1.73 ± 0.86 |
| Pfkb3         | PFK2       | 1.05 ± 0.13 | 1.17 ± 0.19 | 1.22 ± 0.19 |
| Nrlh3         | Lxr-α      | 1.03 ± 0.11 | 0.81 ± 0.03 | 0.91 ± 0.05 |
| Fasn          | FAS        | 1.14 ± 0.21 | 11.37 ± 5.76* | 2.33 ± 0.42 |
| Mod1          | ME         | 1.05 ± 0.13 | 2.43 ± 0.91 | 1.57 ± 0.32 |
| Myc           | c-myc      | 1.07 ± 0.26 | 3.29 ± 1.49 | 0.94 ± 0.19 |
| Sreb1f        | SREBP1c    | 1.03 ± 0.10 | 0.90 ± 0.16 | 0.85 ± 0.11 |
| Chrebp        | CHREBP     | 1.08 ± 0.12 | 2.31 ± 0.72 | 1.90 ± 0.29 |
| Gluconeogenesis | | | | |
| Pck1          | PEPCK-C    | 1.04 ± 0.12 | 0.52 ± 0.11* | 0.91 ± 0.16 |
| G6pc          | Glc-6Pase  | 0.95 ± 0.31 | 1.70 ± 0.56 | 4.52 ± 1.39* |
| Hnf4          | HNF-4α     | 1.05 ± 0.13 | 0.68 ± 0.07 | 0.77 ± 0.12 |
| Slc2a2        | GLUT-2     | 1.01 ± 0.05 | 1.20 ± 0.25 | 1.01 ± 0.12 |
| Energy metabolism | | | | |
| Cpt1a         | Cpt-1α     | 1.02 ± 0.09 | 0.83 ± 0.08* | 0.92 ± 0.08 |
| Hmgs2         | HmgCoA Synthase | 1.02 ± 0.08 | 1.14 ± 0.22 | 0.91 ± 0.11 |
| Mdh1          | cMDH       | 1.01 ± 0.05 | 0.74 ± 0.04* | 0.70 ± 0.10 * |
| Ucp2          | UCP-2      | 1.03 ± 0.10 | 0.66 ± 0.02* | 0.96 ± 0.15 |
| Pparc1        | PGC-1α     | 1.02 ± 0.07 | 0.27 ± 0.07† | 0.63 ± 0.14 * |

Each value on the table represents the mean relative amount of mRNA with respect to that in the control experiment treatment (mean ± SE). Liver gene expression profile was analyzed by qRT-PCR using Applied Biosystems 7900HT Micro Fluidic Card and ΔΔCt calculations. (N = 5 per group). *P < 0.05 versus pControl; †P < 0.05 versus pControl and pGK; ‡P < 0.001 versus pControl and P < 0.05 versus pGKA456V.
Figure 5: Analysis of protein levels in livers transfected with GK and GK\textsubscript{A456V}. Livers excised from mice in postabsorptive state were homogenized and resolved by Western blot. (a, b) Representative blots from three independent experiments. The densitometric analysis is presented ($N = 4$, $^*P < 0.05$ versus pControl, $^{***}P < 0.001$ versus pGK\textsubscript{A456V}). (c) Liver sections of 5-hour fasted mice injected with pControl, pGK, or pGK\textsubscript{A456V} were immunostained with Glc6Pase antibody. TO-PRO-3 was used to visualize nuclei.
allowed us to obtain a mouse model where the effects of exogenous Gks are isolated from those of endogenous GK (undetectable levels of mouse GK mRNA and activity in pControl-treated animals) and insulin action (insulin levels <0.1 µg/L in all treatment groups). In addition, the use of hydrodynamic gene transfer provides proper zonal expression of GK and GKa456V in perivenous hepatocytes [23, 25]. The efficiency of this gene transfer technique is variable. Therefore, only animals that were positive for exogenous expression of GK as determined by qRT-PCR (3x SD of controls) were selected for further analysis (data not shown). After selection, both GK-overexpressing groups had identical protein levels and maximal activity (100 mM glucose) Figures 1(a)–1(b). These results are not in agreement with the reported instability of liver GK protein in a PHH–GKa456V transgenic mouse [28] and the GKR knock-out model [37, 38], probably because of the lack of endogenous transcriptional control in pGKa456V. Also, GKa456V activity at 5 mM glucose was higher in liver extracts, as expected from the kinetic changes associated with the mutation.

The GKa456V mutation resides on a hinge of the enzyme responsible for the conformational changes associated with GKR interaction and allosteric activation. GKR regulates GK action in hepatocytes by retaining the enzyme in the nucleus at low glucose concentrations and liberating GK when insulin, high glucose levels, or fructose-1P is present [26, 27]. We show here that GKa456V is predominantly cytosolic in the liver of transfected animals, contrary to the expected nuclear compartmentalization of wild-type GK. In addition, GKa456V was not appropriately translocated to the nucleus of diabetic primary hepatocytes in the presence of excess GKR (data not shown). Lack of GKR binding to GKa456V has been shown by Heredia et al. [6] in vitro and inferred from the structural characterization of GK bound to synthetic activators [12, 39]. Recent reports on the P446L mutation in GKR also suggest that a decrease in GK inhibition results in increased GK activity, suggesting that GK localizes to the cytosol [13].

An analysis of GK and GKa456V overexpression in well-fed animals demonstrated small but significant changes in glycemia, together with increased hepatic glucose metabolism, as suggested by higher F2,6BP and glycogen content, in the absence of alterations to lipid serum metabolites. No changes were observed in enzymes or regulatory proteins involved in gluconeogenesis in fed animals (data not shown). These results are partially consistent with the phenotype observed by Morrall et al. [31, 33, 40], who used a low dose of GK-expressing adenovirus (expressed largely in periportal hepatocytes, [41, 42]) but differ from those obtained using high doses of adenovirus, indicating that dose and/or zonal expression of GK influences the metabolic impact of GK overexpression.

When animals were examined after a short fast (postabsorptive), marked differences were observed among groups.

1. GK overexpression reduced glycemia ~15%, consistent with enhanced glucose metabolism in the liver, as shown by increased G6P, F2,6BP, glycogen content, and glycolytic and lipogenic enzymes together with higher serum lactate, NEFA and TAG concentrations. Matsuzaka et al. [43] have shown that a fed-to-fast transition in STZ-diabetic mice results in increased gluconeogenic potential and fatty acid oxidation in the liver, consistent with results obtained in pControl-treated animals in the present study. Conversely, pGK treatment resulted in reduced PEPCk and PGC1α mRNA, supporting the view that GK overexpression indirectly inhibits gluconeogenesis and fatty-acid oxidation. Consistently, we measured higher NEFA and TAG serum levels in the postabsorptive state although no changes in β-hydroxybutyrate were observed. These results indicate that enhanced glucose metabolism resulting from GK overexpression had a small effect on glyceremia, possibly because pGK dose was low.

2. GKa456V overexpression led to a significant reduction of serum glucose of ~60% that was consistent with higher glucose clearance on a glucose tolerance test in fasting, healthy mice. Fasting hypoglycemia is also observed in human carriers of the P446L GKR mutation [14, 44]. GKa456V overexpression did not impact the concentration of serum lipids whereas β-hydroxybutyrate was increased, contrary to the dyslipidemia observed in GK overexpressing animals in this and earlier studies, including human carriers of the P446L GKR mutation [14, 44]. Both kinetic and regulatory issues might account for the observed differences.

Hepatic levels of F2,6BP and L-PK protein were increased but other indicators (G6P, Fasn mRNA, ChREBP protein, and mRNA and glycosgen content) of glucose utilization were lower than in GK-expressing livers. Importantly, glycolysis balance (fed-to-fast) was significantly lower in GKa456V-expressing animals, indicating an important net loss of glycogen. G6Pase expression was also higher in this group of animals, providing an explanation for increased glycogen loss observed in GKa456V-containing livers. The involvement of G6Pase in the positive regulation of glycogenolysis has been shown in several animal models overexpressing P36 or P46 components of the G6Pase system, resulting in decreased glycogen levels in the hepatocyte [45–48]. Moreover, a lack of G6Pase system activity observed in glycogen storage disease type 1a, or in a G6Pase KO promotes glycogen accumulation [49]. Activation of the nonoxidative branch of the pentose phosphate pathway, as a result of high exogenous glucose, transiently upmodulates G6Pase mRNA levels and stability in an insulin-independent manner [34, 35]. GKa456V-expressing livers showed higher G6PDH activity and GSH/GSSG ratio during the fed-to-fast transition than control or GK groups (Figures 4(c)–4(d) and Table 1). Increased G6Pase mRNA and protein in the presence of GKa456V would suggest an induction of glucose cycling. The physiological explanations for this futile pathway are not completely understood. It is, however, clear that this counter regulation shall have consequential effects on glucose homeostasis if persistent, as occurs in the GKa456V model.

All in all, the present data confirms that pGK overexpression in the liver results in relatively small changes in glycemia but overt didipidemia. The present model represents the first attempt to overexpress pGK in perivenous hepatocytes, and confirms previous observations using adenovirus [29]. In contrast to the work of Scott et al. [50] and Morrall et al. [40], GK overexpression in perivenous hepatocytes...
does not significantly affect Glc6Pase expression, suggesting that zonation is an important experimental variable not sufficiently addressed to date in the field. In addition, we have demonstrated that GK \( \text{A456V} \) overexpression reduces blood glucose to a great extent, probably due to its capacity to induce Glc6Pase.

We conclude that impaired GKR P regulation and GK \( \text{A456V} \) altered kinetics greatly influence liver metabolism, in line with results obtained in humans with a mutant GKR P. Besides, it suggests that activating GK exclusively in the liver could be a feasible strategy for diabetes, widening the scope for GKA research. Similar conclusions, based on its potent induction of glucose clearance by the liver, have been obtained after liver-specific GK activation in chicken in a recent study by Rideau et al. \[51\]. Studies on animal models of type 2 diabetes are under way in our laboratory in order to evaluate the metabolic impact in the context of insulin resistance and obesity.

Acknowledgments
The authors would like to thank Sandra M. Ocampo, Francesc X. Blasco, and the Research Support Services from the Biology Unit of Bellvitge (University of Barcelona) for their technical assistance and Dr. Maria Molas for invaluable assistance in reviewing the manuscript. A. V. Alabró received a fellowship from DURSI (Generalitat de Catalunya). A. Méndez-Lucas received a fellowship from FPI (Ministerio de Educación y Ciencia). This work was supported by a grant from the Ministerio de Educación y Ciencia (BFU2006-02802).

References

[1] T. L. Jetton, Y. Liang, C. C. Pettepher et al., "Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut," *Journal of Biological Chemistry*, vol. 269, no. 5, pp. 3641–3654, 1994.

[2] F. C. Schuit, P. Huypens, H. Heimberg, and D. G. Pipeleers, "Glucose sensing in pancreatic \( \beta \)-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus," *Diabetes*, vol. 50, no. 1, pp. 1–11, 2001.

[3] D. Zelent, M. L. Golson, B. Koeberlein et al., "A glucose sensor role for glucokinase in anterior pituitary cells," *Diabetes*, vol. 55, no. 7, pp. 1923–1929, 2006.

[4] E. Van Schaftingen, A. Vandercammen, M. Detheux, and D. R. Davies, "The regulatory protein of liver glucokinase," *Advances in Enzyme Regulation*, vol. 32, pp. 133–148, 1992.

[5] E. Alvarez, I. Roncero, J. A. Chowen, P. Vázquez, and E. Blázquez, "Evidence that glucokinase regulatory protein is expressed and interacts with glucokinase in rat brain," *Journal of Neurochemistry*, vol. 80, no. 1, pp. 45–53, 2002.

[6] V. V. Heredia, T. J. Carlson, E. Garcia, and S. Sun, "Biochemical basis of glucokinase activation and the regulation by glucokinase regulatory protein in naturally occurring mutations," *Journal of Biological Chemistry*, vol. 281, no. 52, pp. 40201–40207, 2006.

[7] F. M. Matschinsky, "Assessing the potential of glucokinase activators in diabetes therapy," *Nature Reviews Drug Discovery*, vol. 8, no. 5, pp. 399–416, 2009.

[8] J. Grimsby, R. Sarabu, W. L. Corbett et al., "Allosteric activators of glucokinase: potential role in diabetes therapy," *Science*, vol. 301, no. 5631, pp. 370–373, 2003.

[9] A. M. EfanoV, D. G. Barrett, M. B. Brenner et al., "A novel glucokinase activator modulates pancreatic islet and hepatocyte function," *Endocrinology*, vol. 146, no. 9, pp. 3696–3701, 2005.

[10] B. Leighton, A. Atkinson, and M. P. Coghlan, "Small molecule glucokinase activators as novel anti-diabetic agents," *Biochemical Society Transactions*, vol. 33, no. 2, pp. 371–374, 2005.

[11] K. J. Brocklehurst, V. A. Payne, R. A. Davies et al., "Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators," *Diabetes*, vol. 53, no. 3, pp. 535–541, 2004.

[12] M. Futamura, H. Hosaka, A. Kadotani et al., "An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism," *Journal of Biological Chemistry*, vol. 281, no. 49, pp. 37668–37674, 2006.

[13] N. L. Beer, N. D. Tribble, L. J. McCulloch et al., "The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver," *Human Molecular Genetics*, vol. 18, no. 21, pp. 4081–4088, 2009.

[14] M. Vaxillaire, C. Cavalcanti-Proença, A. Dechaume et al., "The common P446L polymorphism in GCKR inversely modulates fasting glucose and triglyceride levels and reduces type 2 diabetes risk in the DESIR prospective general French population," *Diabetes*, vol. 57, no. 8, pp. 2253–2257, 2008.

[15] H. Niwa, K. Yamamura, and J. Miyazaki, "Efficient selection for high-expression transfectants with a novel eukaryotic vector," *Gene*, vol. 108, no. 2, pp. 193–200, 1991.

[16] Z. Y. Chen, C. Y. He, L. Meuse, and M. A. Kay, "Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo," *Gene Therapy*, vol. 11, no. 10, pp. 856–864, 2004.

[17] Z.-Y. Chen, S. R. Yant, C.-Y. He, L. Meuse, S. Shen, and M. A. Kay, "Linear DNAs concatemerize in vivo and result in sustained transgene expression in mouse liver," *Molecular Therapy*, vol. 3, no. 3, pp. 403–410, 2001.

[18] Y. K. Song, F. Liu, G. Zhang, and D. Liu, "Hydrodynamics-based transfection: simple and efficient method for introducing and expressing transgenes in animals by intravenous injection of DNA," *Methods in Enzymology*, vol. 346, Article ID 5, pp. 92–105, 2002.

[19] A. L. Davidson and W. J. Arion, "Factors underlying significant underestimations of glucokinase activity in crude liver extracts: physiological implications of higher cellular activity," *Archives of Biochemistry and Biophysics*, vol. 253, no. 1, pp. 156–167, 1987.

[20] S. R. Pekovich, P. R. Martin, and C. K. Singleton, "Thiamine pyrophosphate-requiring enzymes are altered during pyrimidine-induced thiamine deficiency in cultured human lymphoblasts," *Journal of Nutrition*, vol. 126, no. 7, pp. 1791–1798, 1996.

[21] E. Van Schaftingen, B. Lederer, R. Bartrons, and H. G. Hers, "A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate," *European Journal of Biochemistry*, vol. 129, no. 1, pp. 191–195, 1982.

[22] P. Hakimi, M. T. Johnson, J. Yang et al., "Phosphoenolpyruvate carboxykinase and the critical role of cataplerosis in the...
control of hepatic glucose production, "Nature Medicine, vol. 2, article no. 33, 2005.
[23] A. G. Gómez-Valadés, A. Vidal-Alabró, M. Molas et al., "Overcoming diabetes-induced hyperglycemia through inhibition of hepatic phosphoenolpyruvate carboxykinase (GTP) with RNAi," _Molecular Therapy_, vol. 13, no. 2, pp. 401–410, 2006.
[24] V. G. Budker, V. M. Subbotin, T. Budker, M. G. Sebestyén, G. Zhang, and J. A. Wolff, "Mechanism of plasmid delivery by hydrodynamic tail vein injection. II. Morphological studies," _Journal of Gene Medicine_, vol. 8, no. 7, pp. 874–888, 2006.
[25] T. Kietzmann, U. Roth, S. Freimann, and K. Jungermann, "Arterial oxygen partial pressures reduce the insulin-dependent induction of the peripherally located glucokinase in rat hepatocyte cultures: mimicry of arterial oxygen pressures by H2O2," _Biochemical Journal_, vol. 321, no. 1, pp. 17–20, 1997.
[26] D. Bosco, P. Meda, and P. B. Iynedjian, "Glucokinase and glucokinase regulatory protein: mutual dependence for nuclear localization," _Biochemical Journal_, vol. 348, no. 1, pp. 215–222, 2000.
[27] N. De La Iglesias, M. Mukhtar, J. Seoane, J. J. Guinovart, and L. Agius, "The role of the regulatory protein of glucokinase in the glucose sensory mechanism of the hepatocyte," _Journal of Biological Chemistry_, vol. 275, no. 14, pp. 10597–10603, 2000.
[28] M. E. Piné, K. A. Kim, K. D. Shelton et al., "Glucokinase thermolability and hepatic regulatory protein binding are essential factors for predicting the blood glucose phenotype of missense mutations," _Journal of Biological Chemistry_, vol. 282, no. 18, pp. 13906–13916, 2007.
[29] R. M. O’Doherty, D. L. Lehman, S. Télémague-Potts, and C. R. Newgard, "Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia," _Diabetes_, vol. 48, no. 10, pp. 2022–2027, 1999.
[30] T. Ferre, A. Pujol, E. Riu, F. Bosch, and A. Valera, "Correction of diabetic alterations by glucokinase," _Proceedings of the National Academy of Sciences of the United States of America_, vol. 93, no. 14, pp. 7225–7230, 1996.
[31] N. Morral, "Gene therapy for type 1 diabetes: new approaches," _Minerva Medica_, vol. 95, no. 2, pp. 93–104, 2004.
[32] T. Ferre, E. Riu, F. Franckhauser, J. Agudo, and F. Bosch, "Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance," _Diabetologia_, vol. 46, no. 12, pp. 1662–1668, 2003.
[33] N. Morral, R. McEvoy, H. Dong et al., "Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes," _Human Gene Therapy_, vol. 13, no. 13, pp. 1561–1570, 2002.
[34] D. Massillon, "Regulation of the glucose-6-phosphatase gene by glucose occurs by transcriptional and post-transcriptional mechanisms. Differential effect of glucose and xylitol," _Journal of Biological Chemistry_, vol. 276, no. 6, pp. 4055–4062, 2001.
[35] D. Massillon, W. Chen, N. Barzilai et al., "Carbon flux via the pentose phosphate pathway regulates the hepatic expression of the glucose-6-phosphatase and phosphoenolpyruvate carboxykinase genes in conscious rats," _Journal of Biological Chemistry_, vol. 273, no. 1, pp. 228–234, 1998.
[36] C. Wu, D. A. Okar, C. B. Newgard, and A. J. Lange, "Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in mouse liver lowers blood glucose by suppressing hepatic glucose production," _Journal of Clinical Investigation_, vol. 107, no. 1, pp. 91–98, 2001.
[37] D. Farrelly, K. S. Brown, A. Tieman et al., "Mice mutant for glucokinase regulatory protein exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation," _Proceedings of the National Academy of Sciences of the United States of America_, vol. 96, no. 25, pp. 14511–14516, 1999.
[38] J. Grimsby, J. W. Coffey, M. T. Dvorozniak et al., "Characterization of glucokinase regulatory protein-deficient mice," _Journal of Biological Chemistry_, vol. 275, no. 11, pp. 7826–7831, 2000.
[39] K. Kamata, M. Mitsuya, T. Nishimura, J. I. Eiki, and Y. Nagata, "Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase," _Structure_, vol. 12, no. 3, pp. 429–438, 2004.
[40] N. Morral, H. J. Edenberg, S. R. Witting, J. Altomonte, T. Chu, and M. Brown, "Effects of glucose metabolism on the regulation of genes of fatty acid synthesis and triglyceride secretion in the liver," _Journal of Lipid Research_, vol. 48, no. 7, pp. 1499–1510, 2007.
[41] P. Lefesvre, J. Attema, A. Lemckert, M. Havenga, and D. van Bekkum, "Genetic heterogeneity in response to adenovirus gene therapy," _BMC Molecular Biology_, vol. 4, article no. 4, 2003.
[42] R. J. Noel, _Prospects for Genetic Manipulation in Diabetes_, Elsevier, Amsterdam, The Netherlands, 1996.
[43] T. Matsuzaka, H. Shimano, N. Yahagi et al., "Insulin-independent induction of sterol regulatory element-binding protein-1c expression in the livers of streptozotocin-treated mice," _Diabetes_, vol. 53, no. 3, pp. 560–569, 2004.
[44] T. Sparso, G. Andersen, T. Nielsen et al., "The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting andOGTT-related insulinemia, and reduced risk of type 2 diabetes," _Diabetologia_, vol. 51, no. 1, pp. 70–75, 2008.
[45] J. An, Y. Li, G. Van De Werve, and C. B. Newgard, "Overexpression of the P46 (T1) translocase component of the glucose-6-phosphatase complex in hepatocytes impairs glycogen accumulation via hydrolysis of glucose 1-phosphate," _Journal of Biological Chemistry_, vol. 276, no. 14, pp. 10722–10729, 2001.
[46] J. Seoane, K. Trinh, R. M. O’Doherty et al., "Metabolic impact of adenovirus-mediated overexpression of the glucose-6-phosphatase catalytic subunit in hepatocytes," _Journal of Biological Chemistry_, vol. 272, no. 43, pp. 26972–26977, 1997.
[47] S. Aiston, K. Y. Trinh, A. J. Lange, C. B. Newgard, and L. Agius, "Glucose-6-phosphatase overexpression lowers glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting glucokinase translocation. Evidence against feedback inhibition of glucokinase," _Journal of Biological Chemistry_, vol. 274, no. 35, pp. 24559–24566, 1999.
[48] K. Y. Trinh, R. M. O’Doherty, P. Anderson, A. J. Lange, and C. B. Newgard, "Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats," _Journal of Biological Chemistry_, vol. 273, no. 47, pp. 31615–31620, 1998.
[49] G. Van De Werve, A. Lange, C. Newgard, M. C. Méchin, Y. Li, and A. Berteloot, "New lessons in the regulation of glucose metabolism taught by the glucose 6-phosphatase system," _European Journal of Biochemistry_, vol. 267, no. 6, pp. 1533–1549, 2000.
[50] D. K. Scott, J. J. Collier, T. T. T. Doan et al., "A modest glucokinase overexpression in the liver promotes fed expression levels..."
of glycolytic and lipogenic enzyme genes in the fasted state without altering SREBP-1c expression,” *Molecular and Cellular Biochemistry*, vol. 254, no. 1-2, pp. 327–337, 2003.

[51] N. Rideau, M. Derouet, J. Grimsby, and J. Simon, “Gluco kinase activation induces potent hypoglycemia without recruiting insulin and inhibits food intake in chicken,” *General and Comparative Endocrinology*, vol. 169, no. 3, pp. 276–283, 2010.